CNTX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Stats
Today's Volume	118 412
Average Volume	570 430
Market Cap	148.50M
EPS	$0 ( 2024-05-08 )
Next earnings date	( $-0.170 ) 2024-08-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.490
ATR14	$0.00500 (0.26%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-21	Minai-azary Jennifer Lynn	Buy	160 115	Stock Option (right to buy)
2024-03-21	Levit Alex C.	Buy	153 515	Stock Option (right to buy)
2024-03-21	Lehr Martin A.	Buy	291 402	Stock Option (right to buy)
2023-05-31	Kantoff Philip W.	Buy	25 000	Stock Option (right to buy)
2023-05-31	West Linda	Buy	25 000	Stock Option (right to buy)

INSIDER POWER
100.00
Last 72 transactions
Buy: 4 162 098 \| Sell: 2 098 089

Volume Correlation

Long: 0.09 (neutral)

Short: -0.41 (neutral)

Signal:(44.988) Neutral

Context Therapeutics Inc. Correlation

10 Most Positive Correlations
THCP	0.933
IZEA	0.93
SGMA	0.93
USAP	0.925
DINT	0.925
IBRX	0.922
JAGX	0.919
AEYE	0.918
LSAK	0.914
VITL	0.913

10 Most Negative Correlations
OZEM	-1
HGBL	-0.909
LINK	-0.907
VRSN	-0.905
APDN	-0.903
ASNS	-0.896
ISSC	-0.89
TOI	-0.887
ARAY	-0.885
III	-0.882

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Context Therapeutics Inc. Correlation - Currency/Commodity

-0.67
( moderate negative )

-0.44
( neutral )

0.00
( neutral )

-0.59
( weak negative )

0.54
( weak )

Context Therapeutics Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-12 044.00 (0.00 %)
EPS:	$-1.500

FY	2023
Revenue:	$0
Gross Profit:	$-12 044.00 (0.00 %)
EPS:	$-1.500

FY	2022
Revenue:	$0
Gross Profit:	$-9 268.00 (0.00 %)
EPS:	$-0.900

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.024

Financial Reports:

No articles found.

Context Therapeutics Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Context Therapeutics Inc.

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.